Cargando…

CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019

The morbidity of coronary artery disease (CAD) in the Uygur population of Xinjiang was much higher than the national average. Clopidogrel is the most commonly used medication worldwide in dual antiplatelet therapy for CAD, and the response of clopidogrel is affected by CYP2C19, PON1, and ABCB1 genet...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tingting, Zhao, Ting, Bao, Sichen, Jia, Li, Feng, Jie, Yu, Aiping, Sun, Li, Guo, Xihong, Li, Hongjian, Yu, Luhai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373584/
https://www.ncbi.nlm.nih.gov/pubmed/32702814
http://dx.doi.org/10.1097/MD.0000000000020582
_version_ 1783561522134384640
author Wang, Tingting
Zhao, Ting
Bao, Sichen
Jia, Li
Feng, Jie
Yu, Aiping
Sun, Li
Guo, Xihong
Li, Hongjian
Yu, Luhai
author_facet Wang, Tingting
Zhao, Ting
Bao, Sichen
Jia, Li
Feng, Jie
Yu, Aiping
Sun, Li
Guo, Xihong
Li, Hongjian
Yu, Luhai
author_sort Wang, Tingting
collection PubMed
description The morbidity of coronary artery disease (CAD) in the Uygur population of Xinjiang was much higher than the national average. Clopidogrel is the most commonly used medication worldwide in dual antiplatelet therapy for CAD, and the response of clopidogrel is affected by CYP2C19, PON1, and ABCB1 genetic polymorphisms. The distribution of CYP2C19∗17, ABCB1, and PON1 genetic polymorphisms in Han and Uygur populations with CAD of Xinjiang has not been investigated. This study aimed to investigate the frequencies of CYP2C19, PON1, and ABCB1 genetic polymorphisms, and to identify the metabolizer phenotype of CYP2C19 in Han and Uygur populations with CAD in Northwestern Xinjiang, China. We identified 602 Han and 527 Uygur patients from 2014 through 2019 and studied genotypes for selected allele polymorphisms using sequencing by hybridization. There were significantly different allele frequencies and genotype frequencies between the 2 ethnic groups in terms of CYP2C19∗2, ∗3, ∗17, ABCB1 and PON1, (P < .05). For CYP2C19∗17, the frequency of TT genotype was 2.5% in Uygur patients, but it was undetectable in Han patients. In both the intermediate and poor metabolizer groups, the genotypes polymorphisms CYP2C19∗2, ∗3, ∗17 were significantly less common in Uygur patients than in Han patients (P < .001). By contrast, the proportion of ultra-metabolizers as defined by CYP2C19∗2, ∗3, ∗17 polymorphisms significantly higher in Uygur patients (18.6%) than in Han patients (1.7%, P < .001). The CYP2C19∗2 frequency was significantly different between Han patients and Han healthy groups (P < .001), while the CYP2C19∗3 frequency was significantly different between Uygur patients and Uygur healthy groups (P < .001). Our study supports the notion of interethnic differences in terms of CYP2C19, PON1, and ABCB1 polymorphisms and CYP2C19 genotype-defined clopidogrel metabolic groups. These finding could provide valuable data and insights into personalized CAD treatment for the Uygur and Han populations in Xinjiang.
format Online
Article
Text
id pubmed-7373584
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-73735842020-08-05 CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019 Wang, Tingting Zhao, Ting Bao, Sichen Jia, Li Feng, Jie Yu, Aiping Sun, Li Guo, Xihong Li, Hongjian Yu, Luhai Medicine (Baltimore) 3500 The morbidity of coronary artery disease (CAD) in the Uygur population of Xinjiang was much higher than the national average. Clopidogrel is the most commonly used medication worldwide in dual antiplatelet therapy for CAD, and the response of clopidogrel is affected by CYP2C19, PON1, and ABCB1 genetic polymorphisms. The distribution of CYP2C19∗17, ABCB1, and PON1 genetic polymorphisms in Han and Uygur populations with CAD of Xinjiang has not been investigated. This study aimed to investigate the frequencies of CYP2C19, PON1, and ABCB1 genetic polymorphisms, and to identify the metabolizer phenotype of CYP2C19 in Han and Uygur populations with CAD in Northwestern Xinjiang, China. We identified 602 Han and 527 Uygur patients from 2014 through 2019 and studied genotypes for selected allele polymorphisms using sequencing by hybridization. There were significantly different allele frequencies and genotype frequencies between the 2 ethnic groups in terms of CYP2C19∗2, ∗3, ∗17, ABCB1 and PON1, (P < .05). For CYP2C19∗17, the frequency of TT genotype was 2.5% in Uygur patients, but it was undetectable in Han patients. In both the intermediate and poor metabolizer groups, the genotypes polymorphisms CYP2C19∗2, ∗3, ∗17 were significantly less common in Uygur patients than in Han patients (P < .001). By contrast, the proportion of ultra-metabolizers as defined by CYP2C19∗2, ∗3, ∗17 polymorphisms significantly higher in Uygur patients (18.6%) than in Han patients (1.7%, P < .001). The CYP2C19∗2 frequency was significantly different between Han patients and Han healthy groups (P < .001), while the CYP2C19∗3 frequency was significantly different between Uygur patients and Uygur healthy groups (P < .001). Our study supports the notion of interethnic differences in terms of CYP2C19, PON1, and ABCB1 polymorphisms and CYP2C19 genotype-defined clopidogrel metabolic groups. These finding could provide valuable data and insights into personalized CAD treatment for the Uygur and Han populations in Xinjiang. Wolters Kluwer Health 2020-07-17 /pmc/articles/PMC7373584/ /pubmed/32702814 http://dx.doi.org/10.1097/MD.0000000000020582 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle 3500
Wang, Tingting
Zhao, Ting
Bao, Sichen
Jia, Li
Feng, Jie
Yu, Aiping
Sun, Li
Guo, Xihong
Li, Hongjian
Yu, Luhai
CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title_full CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title_fullStr CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title_full_unstemmed CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title_short CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019
title_sort cyp2c19, pon1, and abcb1 gene polymorphisms in han and uygur populations with coronary artery disease in northwestern xinjiang, china, from 2014 through 2019
topic 3500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373584/
https://www.ncbi.nlm.nih.gov/pubmed/32702814
http://dx.doi.org/10.1097/MD.0000000000020582
work_keys_str_mv AT wangtingting cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT zhaoting cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT baosichen cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT jiali cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT fengjie cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT yuaiping cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT sunli cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT guoxihong cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT lihongjian cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019
AT yuluhai cyp2c19pon1andabcb1genepolymorphismsinhananduygurpopulationswithcoronaryarterydiseaseinnorthwesternxinjiangchinafrom2014through2019